158 related articles for article (PubMed ID: 14989458)
1. Evolution of renal pathology in Fabry disease.
Sessa A; Meroni M; Battini G; Righetti M; Nebuloni M; Tosoni A; Vago GL;
Acta Paediatr Suppl; 2003 Dec; 92(443):6-8; discussion 5. PubMed ID: 14989458
[TBL] [Abstract][Full Text] [Related]
2. Renal ultrastructural findings in Anderson-Fabry disease.
Sessa A; Toson A; Nebuloni M; Pallotti F; Giordano F; Battini G; Maglio A; Meroni M; Calconi G; Bertolone G; Gatti P
J Nephrol; 2002; 15(2):109-12. PubMed ID: 12018625
[TBL] [Abstract][Full Text] [Related]
3. Renal pathological changes in Fabry disease.
Sessa A; Meroni M; Battini G; Maglio A; Brambilla PL; Bertella M; Nebuloni M; Pallotti F; Giordano F; Bertagnolio B; Tosoni A
J Inherit Metab Dis; 2001; 24 Suppl 2():66-70; discussion 65. PubMed ID: 11758681
[TBL] [Abstract][Full Text] [Related]
4. Renal involvement in Anderson-Fabry disease.
Sessa A; Meroni M; Battini G; Righetti M; Maglio A; Tosoni A; Nebuloni M; Vago G; Giordano F
J Nephrol; 2003; 16(2):310-3. PubMed ID: 12774774
[TBL] [Abstract][Full Text] [Related]
5. Anderson-Fabry disease: a multiorgan disease.
Tuttolomondo A; Pecoraro R; Simonetta I; Miceli S; Pinto A; Licata G
Curr Pharm Des; 2013; 19(33):5974-96. PubMed ID: 23448451
[TBL] [Abstract][Full Text] [Related]
6. Scoring system for renal pathology in Fabry disease: report of the International Study Group of Fabry Nephropathy (ISGFN).
Fogo AB; Bostad L; Svarstad E; Cook WJ; Moll S; Barbey F; Geldenhuys L; West M; Ferluga D; Vujkovac B; Howie AJ; Burns A; Reeve R; Waldek S; Noël LH; Grünfeld JP; Valbuena C; Oliveira JP; Müller J; Breunig F; Zhang X; Warnock DG;
Nephrol Dial Transplant; 2010 Jul; 25(7):2168-77. PubMed ID: 19833663
[TBL] [Abstract][Full Text] [Related]
7. Globotriaosylceramide accumulation in the Fabry kidney is cleared from multiple cell types after enzyme replacement therapy.
Thurberg BL; Rennke H; Colvin RB; Dikman S; Gordon RE; Collins AB; Desnick RJ; O'Callaghan M
Kidney Int; 2002 Dec; 62(6):1933-46. PubMed ID: 12427118
[TBL] [Abstract][Full Text] [Related]
8. Novel frameshift mutation in a heterozygous woman with Fabry disease and end-stage renal failure.
Van Loo A; Vanholder R; Madsen K; Praet M; Kint J; De Paepe A; Messiaen L; Lameire N; Hasholt L; Sørensen SA; Ringoir S
Am J Nephrol; 1996; 16(4):352-7. PubMed ID: 8739292
[TBL] [Abstract][Full Text] [Related]
9. [Fabry nephropathy in a female with superposed IgA glomerulonephritis].
Pisani A; Sessa A; Sabbatini M; Andreucci MV; Fusco C; Balletta M; Cianciaruso B
G Ital Nefrol; 2005; 22(4):385-9. PubMed ID: 16267800
[TBL] [Abstract][Full Text] [Related]
10. Fabry disease: renal biopsy-proven cases from China.
Zhang SH; Liu ZH; Zeng CH; Li SJ; Chen HP; Su J; Li LS
J Nephrol; 2007; 20(6):716-26. PubMed ID: 18046674
[TBL] [Abstract][Full Text] [Related]
11. The relationship of vascular glycolipid storage to clinical manifestations of Fabry disease: a cross-sectional study of a large cohort of clinically affected heterozygous women.
Gupta S; Ries M; Kotsopoulos S; Schiffmann R
Medicine (Baltimore); 2005 Sep; 84(5):261-268. PubMed ID: 16148726
[TBL] [Abstract][Full Text] [Related]
12. Kidney biopsy findings in heterozygous Fabry disease females with early nephropathy.
Valbuena C; Carvalho E; Bustorff M; Ganhão M; Relvas S; Nogueira R; Carneiro F; Oliveira JP
Virchows Arch; 2008 Oct; 453(4):329-38. PubMed ID: 18769939
[TBL] [Abstract][Full Text] [Related]
13. Enzyme replacement therapy for Fabry disease, an inherited nephropathy.
Desnick RJ; Banikazemi M; Wasserstein M
Clin Nephrol; 2002 Jan; 57(1):1-8. PubMed ID: 11837797
[TBL] [Abstract][Full Text] [Related]
14. The kidney in Fabry's disease.
Pisani A; Visciano B; Imbriaco M; Di Nuzzi A; Mancini A; Marchetiello C; Riccio E
Clin Genet; 2014 Oct; 86(4):301-9. PubMed ID: 24645664
[TBL] [Abstract][Full Text] [Related]
15. Fabry disease: renal involvement limited to podocyte pathology and proteinuria in a septuagenarian cardiac variant. Pathologic and therapeutic implications.
Meehan SM; Junsanto T; Rydel JJ; Desnick RJ
Am J Kidney Dis; 2004 Jan; 43(1):164-71. PubMed ID: 14712441
[TBL] [Abstract][Full Text] [Related]
16. A characteristic dissection microscopy appearance of a renal biopsy of a Fabry heterozygote.
Yuen NW; Lam CW; Chow TC; Chiu MC
Nephron; 1997; 77(3):354-6. PubMed ID: 9375832
[TBL] [Abstract][Full Text] [Related]
17. Clinical course and pathological findings of two late-onset Fabry hemizygous patients including mulberry cell counts after enzyme replacement therapy.
Shimohata H; Yamashita M; Ohgi K; Maruyama H; Takayasu M; Hirayama K; Kobayashi M
CEN Case Rep; 2020 Aug; 9(3):237-242. PubMed ID: 32189245
[TBL] [Abstract][Full Text] [Related]
18. Ultrastructural study of renal involvement in two females with Anderson-Fabry disease.
Tosoni A; Nebuloni M; Zerbi P; Vago L; Comotti C; Sessa A
Ultrastruct Pathol; 2005; 29(3-4):203-7. PubMed ID: 16036875
[TBL] [Abstract][Full Text] [Related]
19. Kidney histologic alterations in α-Galactosidase-deficient mice.
Valbuena C; Oliveira JP; Carneiro F; Relvas S; Ganhão M; Sá-Miranda MC; Rodrigues LG
Virchows Arch; 2011 Apr; 458(4):477-86. PubMed ID: 21328014
[TBL] [Abstract][Full Text] [Related]
20. Long-term enzyme replacement therapy is associated with reduced proteinuria and preserved proximal tubular function in women with Fabry disease.
Prabakaran T; Birn H; Bibby BM; Regeniter A; Sørensen SS; Feldt-Rasmussen U; Nielsen R; Christensen EI
Nephrol Dial Transplant; 2014 Mar; 29(3):619-25. PubMed ID: 24215016
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
